Amphastar Pharmaceuticals: Evaluating Investment Options Amid Growth Prospects

Amphastar Pharmaceuticals, Inc. is currently rated a Buy, with analysts projecting an approximate 81% upside to a fair value of $33. This optimistic outlook comes despite anticipated margin pressures in 2026, driven by declining sales in legacy products. The company expects to achieve mid- to high-single-digit revenue growth in 2026, primarily fueled by sales of its product Baqsimi and several new launches.

While Amphastar faces challenges with its existing portfolio, analysts see potential for recovery and growth. Operating margins are estimated to dip to 22% in 2026 as expenses increase. However, these margins are expected to recover to 26% by 2030, reflecting the anticipated ramp-up of higher-margin pipeline products.

Investment Strategy Considerations

Given the current market dynamics, a bull Put options strategy is favored over direct equity investments in Amphastar. This preference arises from the company’s limited competitive advantage, or “moat,” and its moderate growth projections. Investors may find this strategy more prudent as it allows for participation in potential upside while mitigating risks associated with direct stock ownership.

In a previous analysis published in July of last year, Amphastar was characterized as undervalued, highlighting its portfolio of both generic and proprietary drugs. This suggests that investors may still find opportunities within the company’s offerings, even amid current challenges.

Analysts emphasize that past performance is not indicative of future results. According to Seeking Alpha, no investment recommendations are provided, and individual investors should conduct their own research to determine suitability.

The insights shared in this article stem from a personal assessment of Amphastar Pharmaceuticals, and the author has disclosed a beneficial long position in AMPH shares through various financial instruments. It is important to note that the views expressed may not reflect the opinions of Seeking Alpha as a whole.

As Amphastar navigates its growth trajectory, investors will be closely monitoring its financial performance and strategic initiatives in the coming years. The balance between managing legacy products and capitalizing on new launches will be critical to the company’s success in the competitive pharmaceutical market.